Figure 9 — The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation

Research Paper|Volume 13, Issue 14|pp. 18545–18563

The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation

Back to articleFigure 9(9 of 9)

100%

Figure 9.Fraxetin enhances the anti-tumor efficacy of gemcitabine and suppresses the oncogenesis and development of PDA via antagonizing STAT3 activation.